The availability of TNF inhibitor biosimilars and the cost of treating ‘difficult-to-treat’ RA are making first-line TNF inhibition in early RA more attractive in the UK.
Dr. Mark S. Komrad has served on the Faculty of Psychiatry at several universities. He is a longtime advocate for safeguarding patients from assisted dying and says psychiatrists are meant to stop ...